CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

Pyruvate Kinase Deficiency Impact Assessment (PKDIA), a weekly measure of disease impacts, measures health-related quality of life, (e.g., daily activities, concentration, physical activity and the ...

Non-small-cell lung cancer (NSCLC) accounts for up to 85% of all cases of lung cancer, which is the most frequent cause of cancer-related deaths worldwide. The need for effective treatments against ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is approaching a ...

Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...

Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. Agios Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

EXTON, PA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest findings from Spherix Global Insights’ syndicated Market Dynamix™ service, the US sickle cell disease (SCD) market is approaching a ...

Tumor M2-PK is becoming established as a good noninvasive screening option for colorectal cancer with a reported sensitivity between 68.8 and 91.0% and an overall specificity ranging from 71.9 to 100% ...

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, ...